StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Gain Therapeutics's operating margin for the twelve months ending Dec 31, 2023 was -40328.3%. For fiscal 2023 it was -40328.3%, against -12688.1% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-40328.3%−27640.2
FY2022Dec 31, 2022-12688.1%−4308.3
FY2021Dec 31, 2021-8379.8%+3667.7
FY2020Dec 31, 2020-12047.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2023Mar 31, 2023-9477.7%+7475.8
Q2 FY2022Jun 30, 2022-5443.0%−1501.7
Q1 FY2022Mar 31, 2022-7306.8%+39512.7
Q4 FY2021Dec 31, 2021-7426.3%+10252.1
Q3 FY2021Sep 30, 2021-16953.5%−4721.0
Q2 FY2021Jun 30, 2021-3941.3%+4413.7
Q1 FY2021Mar 31, 2021-46819.4%−39142.8
Q4 FY2020Dec 31, 2020-17678.5%–
Q3 FY2020Sep 30, 2020-12232.5%–
Q2 FY2020Jun 30, 2020-8355.0%–
Q1 FY2020Mar 31, 2020-7676.6%–

More Gain Therapeutics figures

See a number that looks wrong?